Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
暂无分享,去创建一个
A. Vacca | R. Ria | V. Racanelli | M. Prete | S. Cicco | Antonio Giovanni Solimando | R. Buono | N. Susca | G. Inglese | A. Melaccio
[1] M. Weigand,et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery , 2020, BMC Cardiovascular Disorders.
[2] H. Daida,et al. Neutrophil to Lymphocyte Ratio and Long-Term Cardiovascular Outcomes in Coronary Artery Disease Patients with Low High-Sensitivity C-Reactive Protein Level. , 2020, International heart journal.
[3] M. Picken. The Pathology of Amyloidosis in Classification: A Review , 2020, Acta Haematologica.
[4] G. Cenini,et al. Oxidative Stress and Mitochondrial Damage in Neurodegenerative Diseases: From Molecular Mechanisms to Targeted Therapies , 2020, Oxidative medicine and cellular longevity.
[5] T. Rassaf,et al. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist , 2020, International journal of cardiology. Heart & vasculature.
[6] Asif Khan,et al. Utilization of Ultrasound to Assess Volume Status in Heart Failure , 2020, Journal of clinical medicine research.
[7] James A. White,et al. Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis. , 2020, Canadian Journal of Cardiology.
[8] P. Colonna,et al. Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease , 2019, Clinical and Experimental Medicine.
[9] H. Einsele,et al. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. , 2019, The oncologist.
[10] Y. Takeishi,et al. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis. , 2019, International heart journal.
[11] C. Hagemeyer,et al. Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities , 2019, Front. Cardiovasc. Med..
[12] N. Mahmud,et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant , 2019, Bone Marrow Transplantation.
[13] H. Einsele,et al. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment , 2019, Journal of clinical medicine.
[14] A. Vacca,et al. Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass , 2018, Case reports in hematology.
[15] M. Henein,et al. Right ventricular involvement in transthyretin amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[16] P. Milani,et al. Management of the elderly patient with AL amyloidosis. , 2018, European journal of internal medicine.
[17] M. Dimopoulos,et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. , 2018, Blood.
[18] D. Dingli,et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains , 2018, Leukemia.
[19] Christos G Mihos,et al. A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis. , 2017, Reviews in cardiovascular medicine.
[20] G. Merlini. AL amyloidosis: from molecular mechanisms to targeted therapies. , 2017, Hematology. American Society of Hematology. Education Program.
[21] M. Hanna,et al. Cardiac amyloidosis: An update on diagnosis and treatment , 2017, Cleveland Clinic Journal of Medicine.
[22] P. Milani,et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells , 2017, Scientific Reports.
[23] F. Dammacco,et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. , 2017, Clinical immunology.
[24] O. Berlanga,et al. Immunoparesis defined by heavy+light chain suppression is a novel marker of long‐term outcomes in cardiac AL amyloidosis , 2017, British journal of haematology.
[25] D. Dingli,et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation , 2017, British journal of haematology.
[26] M. Nöthen,et al. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma , 2017, Leukemia.
[27] H. Agis. News in AL Amyloidosis ASH 2016 , 2017, memo - Magazine of European Medical Oncology.
[28] Roman M. Ženka,et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. , 2017, Blood.
[29] M. Dimopoulos,et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. , 2016, Blood.
[30] P. Schirmacher,et al. Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis. , 2016, Journal of the American College of Cardiology.
[31] J. Deux,et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[32] D. Dingli,et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[33] S. Yusuf,et al. Use of Noninvasive Imaging in Cardiac Amyloidosis , 2016, Current Treatment Options in Cardiovascular Medicine.
[34] G. Spadaro,et al. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. , 2016, Clinical immunology.
[35] G. Palladini,et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] A. Jaffe,et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T , 2015, American journal of hematology.
[37] G. Gensini,et al. Echocardiographic and Biohumoral Characteristics in Patients With AL and TTR Amyloidosis at Diagnosis , 2015, Clinical cardiology.
[38] A. Foli,et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.
[39] W. Edwards,et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.
[40] D. Dingli,et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] G. Merlini,et al. Systemic light chain amyloidosis: an update for treating physicians. , 2013, Blood.
[42] G. Merlini,et al. Differential diagnosis of monoclonal gammopathy of undetermined significance. , 2012, Hematology. American Society of Hematology. Education Program.
[43] B. Fernandez,et al. AL Amyloidosis , 2012, Orphanet Journal of Rare Diseases.
[44] L. Padeletti,et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. , 2012, European heart journal cardiovascular Imaging.
[45] R. Falk,et al. Current perspectives on cardiac amyloidosis. , 2012, American journal of physiology. Heart and circulatory physiology.
[46] G. Merlini,et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. , 2012, Blood.
[47] M. Rosenzweig,et al. Light chain (AL) amyloidosis: update on diagnosis and management , 2011, Journal of hematology & oncology.
[48] D. Seldin,et al. Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. , 2011, Heart failure clinics.
[49] R. Rokey,et al. Stiff Heart Syndrome , 2011, Clinical Medicine & Research.
[50] J. Rysä,et al. Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms , 2011, Molecular and Cellular Endocrinology.
[51] W. Aronow,et al. A Novel Two‐Dimensional Echocardiographic Finding in Cardiac Amyloidosis , 2010, Echocardiography.
[52] M. Benson,et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[53] G. Dotti. Blocking PD-1 in cancer immunotherapy. , 2009, Blood.
[54] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[55] W. Manning,et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. , 2009, The American journal of cardiology.
[56] D. Pennell,et al. Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[57] R. Rivera,et al. Cardiac manifestations of amyloid disease. , 2008, Boletin de la Asociacion Medica de Puerto Rico.
[58] Keyur B Shah,et al. Amyloidosis and the heart: a comprehensive review. , 2006, Archives of internal medicine.
[59] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[60] A. Balduini,et al. Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.
[61] C. Martínez,et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. , 2001, Blood.
[62] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[63] M. Terol,et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.
[64] S. Cicco,et al. The influence of oxygen supply, hemorheology and microcirculation in the heart and vascular systems. , 2010, Advances in experimental medicine and biology.
[65] M. Iacoviello,et al. Could dilated cardiomyopathy alter the peripheral microcirculation and blood rheology? , 2010, Advances in experimental medicine and biology.
[66] H. Drexler,et al. Endothelial dysfunction in human disease. , 1999, Journal of molecular and cellular cardiology.